Shanghai Fosun Pharmaceutical fell sharply on its Hong Kong debut on Tuesday, underscoring concerns about weak investor appetite that could pressure new listings in the city in the coming months. Shares of Shanghai Fosun 2196.HK Quote | Chart | News | Profile [2196.HK () ], which raised $512 million last week in the biggest Hong Kong listing in three months, tumbled as much as 12 percent in early trading. That far underperformed a 0.3 percent drop in the benchmark Hang Seng Index .HSI Quote | Chart | News | Profile [.HSI () ]. The drop sends a warning for other deals lining up in Hong Kong, including an up to $6 billion Shanghai-Hong Kong IPO of People's Insurance Company of China (PICC) and...
0 Responses to Fosun Pharma Tumbles in HK Debut, Bodes Ill For New Deals